Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02115815 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 246
- Enrollment target
NCT02115815: Completed Phase 1 study, sponsored by MedImmune.
NCT02115815 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 246 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (310% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02115815, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the administration of single ascending intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions.
Primary Outcome
Solicited symptoms: tenderness or soreness at site of injection, pain at site of injection, fatigue or tiredness, headache, generalized muscle aches, swelling at the site of injection, redness at the site of injection, fever greater than or equal to (\>=) 100.4 degrees F by any route from Day 1 to Day 7.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV sF 20 mcg
- BIOLOGICAL MEDI7510 (20 mcg RSV sF)
- BIOLOGICAL RSV sF 50 mcg
- BIOLOGICAL MEDI7510 (50 mcg RSV sF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
What the finished NCT02115815 record still lists
NCT02115815 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (310% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02115815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02115815 about?
NCT02115815 is a clinical study titled "A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults". The purpose of this study is to determine if the administration of single ascending intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions.
What is the current status of trial NCT02115815?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 246 participants. The study started on 2014-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02115815?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV sF 20 mcg (BIOLOGICAL), MEDI7510 (20 mcg RSV sF) (BIOLOGICAL), RSV sF 50 mcg (BIOLOGICAL), MEDI7510 (50 mcg RSV sF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02115815?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02115815's enrollment target sits among peer trials
246 188th of 2000 higher than 1,812 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia